The estimated Net Worth of Khalid Islam is at least $1.31 Million dollars as of 16 November 2023. Khalid Islam owns over 213,825 units of Fennec Pharmaceuticals Inc stock worth over $1,124,720 and over the last 7 years he sold FENC stock worth over $0. In addition, he makes $190,190 as Independent Chairman of the Board at Fennec Pharmaceuticals Inc.
Khalid has made over 1 trades of the Fennec Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 213,825 units of FENC stock worth $440,480 on 16 November 2023.
The largest trade he's ever made was exercising 213,825 units of Fennec Pharmaceuticals Inc stock on 16 November 2023 worth over $440,480. On average, Khalid trades about 16,448 units every 0 days since 2017. As of 16 November 2023 he still owns at least 213,825 units of Fennec Pharmaceuticals Inc stock.
You can see the complete history of Khalid Islam stock trades at the bottom of the page.
Dr. Khalid Islam Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Khalid Islam was the Chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led the transition from a loss-making to a cash-flow positive and profitable company. Under his leadership, the company value increased from US$25 million leading to a successful all cash US$1 billion merger with Jazz Pharmaceuticals, plc. Subsequent to the sale of Gentium, Dr. Islam has been involved from both an advisory and board level in several public and private healthcare related companies. From 1999-2008, Dr. Islam was President and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised US$300 million in the IPO and follow-ons. From 1987-1999, he held various positions in HMR & MMD (now Sanofi-Aventis). From 1977-1987, Dr. Islam worked in academia at Imperial College (Univ. of London) and in Milan University, where he was a contract professor. Dr. Islam is a graduate of Chelsea College and received his Ph.D. from Imperial College, University of London. He holds several patents and has published over 80 articles in leading journals. He is an advisor to the venture group Kurma Biofund (Paris). He is a founder/co-founder of Sirius Healthcare Partners GmbH (Zurich), PrevAbr LLC (D.C.), BioAim LLC (L.A.) & Life Sciences Management GmbH (Zug). Dr. Islam is Board Chair at Minoryx Therapeutics (Spain) and Gain Therapeutics (Switzerland), a private company. He currently serves on the board of Immunomedics Inc. (IMMU), which is traded publicly. In the past, he has served as Chairman of the Board of Directors of Pcovery Aps (Copenhagen), Adenium Aps (Copenhagen) and C10 Pharma AS (Oslo) and on the board of Karolinska Development (Sweden) and MolMed S.p.A. (Italy). Dr. Islam’s extensive international pharmaceutical expertise in transitioning companies from development to production strengthens the Board’s collective qualifications, skills and experience.
As the Independent Chairman of the Board of Fennec Pharmaceuticals Inc, the total compensation of Khalid Islam at Fennec Pharmaceuticals Inc is $190,190. There are 6 executives at Fennec Pharmaceuticals Inc getting paid more, with Rostislav Raykov having the highest compensation of $1,477,140.
Khalid Islam is 65, he's been the Independent Chairman of the Board of Fennec Pharmaceuticals Inc since 2015. There are 1 older and 8 younger executives at Fennec Pharmaceuticals Inc. The oldest executive at Fennec Pharmaceuticals Inc is Anne McKay, 67, who is the Regulatory Consultant.
Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En..., and Rosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include: